# Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

Study · id `cardio:ct-nct06093932` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06093932](<https://clinicaltrials.gov/study/NCT06093932>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06093932

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06093932. Randomized; double masking; primary purpose treatment. Start 2024-04-07 (actual); primary completion 2024-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06093932, source copy `cardio:ctgov-nct06093932-2024-08-20`, retrieved 2026-10-26)
- Started: 2024-04-07 (actual) (ClinicalTrials.gov record NCT06093932, source copy `cardio:ctgov-nct06093932-2024-08-20`, retrieved 2026-10-26)
- Primary completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT06093932, source copy `cardio:ctgov-nct06093932-2024-08-20`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06093932, source copy `cardio:ctgov-nct06093932-2024-08-20`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06093932, source copy `cardio:ctgov-nct06093932-2024-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06093932-2024-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
- Acronym: ESCIHP
- Condition: Hypertension,Essential
- Intervention (Drug): Songling Xuemaikang Capsules
- Intervention (Behavioral): Lifestyle intervention
- Intervention (Drug): Placebo
- Lead sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Lead sponsor class: OTHER
- Collaborator: Suzhou Hosptial of Traditional Chinese Medicine
- Collaborator class: UNKNOWN
- Collaborator: Shandong University of Traditional Chinese Medicine
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences (`cardio:org-xiyuan-hospital-of-china-academy-of-chinese-medical-sciences`)
- Registry lists this organization as a collaborator: Shandong University of Traditional Chinese Medicine (`cardio:org-shandong-university-of-traditional-chinese-medicine`)

## Provenance

Content hash: 4364f685ada2a5cac89c495ecdcad0265ea30a2cf0c4b6ca9fdee9179bfda624
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
